Medical News Today -- The Medicines Company (NASDAQ: MDCO) today announced the presentation of 2-year clinical results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack were significantly less likely to suffer cardiac death and had better overall survival if treated with Angiomax® (bivalirudin) while undergoing angioplasty compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) during angioplasty. Two-year data of ST-elevation myocardial infarction (STEMI) patients was presented in a late-breaker presentation on September 25, 2009 at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference scientific symposium sponsored by the Cardiovascular Research Foundation.
